As common for our CCs, we have several potential "
Post# of 148190
(Total Views: 492)
Posted On: 03/22/2021 12:36:29 PM
As common for our CCs, we have several potential "meaty" news items, and many potential "updates for more waiting" new items.
NASH and CV19 Longhaulers could be significant.
NASH Phase II Trial completion date March 22nd.
https://clinicaltrials.gov/ct2/history/NCT045...udyPageTop
But the hot topic is CD16 and the changes.
Surprising the CD16 number was increased beyond 140, is that correct?
Might they be adding the 62 from our completed s/c CD12 trial to help get to 140?
If yes, they could start the OLE soon, and give our EUA sooner also.
To announce OLE now, makes it appear that the FDA is anxious, in order to avoid seeming unethical giving folks placebo when LL is known to save lives? (31.8% better than SOC for critical 65 and younger, but small number of patients)
And am I wrong, I thought the 140 CD16 trial was for critical cv19 patients only, no severe?
My Bottom line is, I just double my CYDY position about 30 minutes ago.
NASH and CV19 Longhaulers could be significant.
NASH Phase II Trial completion date March 22nd.
https://clinicaltrials.gov/ct2/history/NCT045...udyPageTop
But the hot topic is CD16 and the changes.
Surprising the CD16 number was increased beyond 140, is that correct?
Might they be adding the 62 from our completed s/c CD12 trial to help get to 140?
If yes, they could start the OLE soon, and give our EUA sooner also.
To announce OLE now, makes it appear that the FDA is anxious, in order to avoid seeming unethical giving folks placebo when LL is known to save lives? (31.8% better than SOC for critical 65 and younger, but small number of patients)
And am I wrong, I thought the 140 CD16 trial was for critical cv19 patients only, no severe?
My Bottom line is, I just double my CYDY position about 30 minutes ago.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼